

Amendments to the Claims:

Please amend claims 1, 2, 4-6, 14-16, and add new claims 22 and 23. This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~A-substance~~ An anti-CD61 antibody, or a derivative thereof, having ~~an ability to bind to a CD61 protein and~~ an inhibitory effect on inflammatory cytokine production, which comprises a heavy chain variable region of the following (a) or (b), and a light chain variable region of the following (c) or (d);

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID

No: 4; or

(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID

NO: 4, wherein not more than 10% of the number of amino acids are mutated by deletion, addition, insertion, and/or substitution, and

(c) a light chain variable region comprising the amino acid sequence of SEQ ID

NO: 8; or

(d) a light chain variable region comprising the amino acid sequence of SEQ ID

NO: 8, wherein not more than 10% of the number of amino acids are mutated by deletion, addition, insertion, and/or substitution.

2. (Currently Amended) ~~The substance or derivative of claim 1, wherein the substance is a protein~~ An anti-CD61 antibody, or a derivative thereof, having an inhibitory effect on inflammatory cytokine production which comprises;

(a) a heavy chain variable region comprising CDR1 to CDR3 which comprises the amino acid sequences of SEQ ID NOs: 1 to 3, respectively, and

(b) a light chain variable region comprising CDR1 to CDR3 which comprises the amino acid sequences of SEQ ID NOs: 5 to 7, respectively.

3. (Canceled)

4. (Currently Amended) The substance antibody or derivative of claim 1 or 2, wherein the inflammatory cytokine is any one of IFN- γ , TNF α , IL-1, and IL-6.

5. (Currently Amended) The substance antibody or derivative of claim 1 or 2, having an IL-10 production-inducing effect.

6. (Currently Amended) ~~An inhibitor of inflammatory cytokine production~~
A composition that inhibits inflammatory cytokine production, comprising as an effective ingredient the substance antibody or derivative of claim 1 or 2.

7.-13. (Canceled)

14. (Currently Amended) A pharmaceutical for preventing or treating inflammatory disease, wherein the pharmaceutical comprises ~~the inhibitor of inflammatory cytokine production of claim 6 or the~~ a chimeric or humanized anti-CD61 antibody of any one of claims 10 to 13 or a derivative thereof.

15. (Currently Amended) A pharmaceutical for preventing or treating hypercytokinemia, wherein the pharmaceutical comprises ~~the inhibitor of inflammatory cytokine production of claim 6 or the~~ a chimeric or humanized anti-CD61 antibody of any one of claims 10 to 13 or a derivative thereof.

16. (Currently Amended) A method for inhibiting inflammatory cytokine production wherein the method comprises a step of administering to a subject in need thereof using the substance an anti-CD61 antibody or a derivative thereof of any one of claims 1 to 5 or the anti-CD61 antibody of any one of claims 10 to 13.

17.- 21. (Canceled)

22. (New) A method for preventing or treating an inflammatory disease, wherein the method comprises the step of administering to a subject in need thereof an anti-CD61 antibody or a derivative thereof.

23. (New) A method for preventing or treating hypercytokinemia, wherein the method comprises the step of administering to a subject in need thereof an anti-CD61 antibody or a derivative thereof.